0001140361-14-031231.txt : 20140807 0001140361-14-031231.hdr.sgml : 20140807 20140807151022 ACCESSION NUMBER: 0001140361-14-031231 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140805 FILED AS OF DATE: 20140807 DATE AS OF CHANGE: 20140807 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Avalanche Biotechnologies, Inc. CENTRAL INDEX KEY: 0001501756 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 205258327 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1035 O?BRIEN DRIVE, SUITE A CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650-272-6269 MAIL ADDRESS: STREET 1: 1035 O?BRIEN DRIVE, SUITE A CITY: MENLO PARK STATE: CA ZIP: 94025 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MCLAUGHLIN JOHN PETER CENTRAL INDEX KEY: 0001277967 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36579 FILM NUMBER: 141023462 MAIL ADDRESS: STREET 1: C/O PDL BIOPHARMA, INC. STREET 2: 932 SOUTHWOOD BOULEVARD CITY: INCLINE VILLAGE STATE: NV ZIP: 89451 4 1 doc1.xml FORM 4 X0306 4 2014-08-05 0 0001501756 Avalanche Biotechnologies, Inc. AAVL 0001277967 MCLAUGHLIN JOHN PETER C/O AVALANCHE BIOTECHNOLOGIES, INC. 1035 O'BRIEN DRIVE, SUITE A MENLO PARK CA 94025 1 0 0 0 Common Stock 2014-08-05 4 C 0 13280 A 13280 I See Footnote Common Stock 2014-08-05 4 C 0 13280 A 13280 I See Footnote Series B Preferred Stock 2014-08-05 4 C 0 13280 D Common Stock 13280 0 I See Footnote Series B Preferred Stock 2014-08-05 4 C 0 13280 D Common Stock 13280 0 I See Footnote Each share of Series A Preferred and Series B Preferred Stock automatically converted into one share of Issuer's Common Stock upon the consummation of the Issuer's initial public offering (the "IPO"). The shares are held directly by the John Peter McLaughlin 2014 Irrevocable Trust. The shares are held directly by the Christopher James McLaughlin 2014 Irrevocable Trust. The Series A Preferred and Series B Preferred Stock automatically converted into shares of Issuer's Common Stock on a 1:1 basis upon the completion of Issuer's IPO. The expiration date is not relevant to the conversion of these securities. /s/ Michael Swartzburg, Attorney-in-Fact for John McLaughlin 2014-08-07